Literature DB >> 25036404

The impact of TP53 and RAS mutations on cerebellar glioblastomas.

Vedrana P Milinkovic1, Milica K Skender Gazibara2, Emilija M Manojlovic Gacic2, Tatjana M Gazibara3, Nikola T Tanic4.   

Abstract

Cerebellar glioblastoma (cGBM) is a rare, inadequately characterized disease, without detailed information on its molecular basis. This is the first report analyzing both TP53 and RAS alterations in cGBM. TP53 mutations were detected in more than half of the samples from our cohort, mainly in hotspot codons. There were no activating mutations in hotspot codons 12/13 and 61 of KRAS and HRAS genes in cGBM samples but we detected alterations in other parts of exons 2 and 3 of these genes, including premature induction of STOP codon. This mutation was present in 3 out of 5 patients. High incidence of RAS mutations, as well as significantly longer survival of cGBM patients compared to those with supratentorial GBM suggest that cGBM may have different mechanisms of occurrence. Our results suggest that inactivation of TP53 and RAS may play an important role in the progression of cerebellar GBM.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cerebellar glioblastoma; Glioblastoma; Immunohistochemistry; RAS; p53

Mesh:

Substances:

Year:  2014        PMID: 25036404     DOI: 10.1016/j.yexmp.2014.07.009

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  7 in total

1.  MicroRNA-134 modulates glioma cell U251 proliferation and invasion by targeting KRAS and suppressing the ERK pathway.

Authors:  Yuguang Zhao; Dong Pang; Cui Wang; Shijiang Zhong; Shuang Wang
Journal:  Tumour Biol       Date:  2016-03-25

2.  Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.

Authors:  Yasuhide Makino; Yoshiki Arakawa; Ema Yoshioka; Tomoko Shofuda; Sachiko Minamiguchi; Takeshi Kawauchi; Masahiro Tanji; Daisuke Kanematsu; Masahiro Nonaka; Yoshiko Okita; Yoshinori Kodama; Masayuki Mano; Takanori Hirose; Yohei Mineharu; Susumu Miyamoto; Yonehiro Kanemura
Journal:  BMC Cancer       Date:  2021-09-15       Impact factor: 4.638

3.  A conserved, N-terminal tyrosine signal directs Ras for inhibition by Rabex-5.

Authors:  Chalita Washington; Rachel Chernet; Rewatee H Gokhale; Yesenia Martino-Cortez; Hsiu-Yu Liu; Ashley M Rosenberg; Sivan Shahar; Cathie M Pfleger
Journal:  PLoS Genet       Date:  2020-06-19       Impact factor: 5.917

4.  MiR-199a Inhibits Tumor Growth and Attenuates Chemoresistance by Targeting K-RAS via AKT and ERK Signalings.

Authors:  Wei Li; Lin Wang; Xiang-Bo Ji; Li-Hong Wang; Xin Ge; Wei-Tao Liu; Ling Chen; Zhong Zheng; Zhu-Mei Shi; Ling-Zhi Liu; Marie C Lin; Jie-Yu Chen; Bing-Hua Jiang
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

Review 5.  Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators.

Authors:  Yuran Qiu; Yuanhao Wang; Zongtao Chai; Duan Ni; Xinyi Li; Jun Pu; Jie Chen; Jian Zhang; Shaoyong Lu; Chuan Lv; Mingfei Ji
Journal:  Acta Pharm Sin B       Date:  2021-02-25       Impact factor: 11.413

6.  Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma.

Authors:  Hee Jin Cho; Junfei Zhao; Sang Won Jung; Erik Ladewig; Doo-Sik Kong; Yeon-Lim Suh; Yeri Lee; Donggeon Kim; Sun Hee Ahn; Mykola Bordyuh; Hyun Ju Kang; Jason K Sa; Yun Jee Seo; Sung Tae Kim; Do Hoon Lim; Yun-Sik Dho; Jung-Il Lee; Ho Jun Seol; Jung Won Choi; Woong-Yang Park; Chul-Kee Park; Raul Rabadan; Do-Hyun Nam
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

7.  Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities.

Authors:  Annekathrin Reinhardt; Damian Stichel; Daniel Schrimpf; Christian Koelsche; Annika K Wefers; Azadeh Ebrahimi; Philipp Sievers; Kristin Huang; M Belén Casalini; Francisco Fernández-Klett; Abigail Suwala; Michael Weller; Dorothee Gramatzki; Joerg Felsberg; Guido Reifenberger; Albert Becker; Volkmar H Hans; Marco Prinz; Ori Staszewski; Till Acker; Hildegard Dohmen; Christian Hartmann; Werner Paulus; Katharina Heß; Benjamin Brokinkel; Jens Schittenhelm; Rolf Buslei; Martina Deckert; Christian Mawrin; Ekkehard Hewer; Ute Pohl; Zane Jaunmuktane; Sebastian Brandner; Andreas Unterberg; Daniel Hänggi; Michael Platten; Stefan M Pfister; Wolfgang Wick; Christel Herold-Mende; Andrey Korshunov; David E Reuss; Felix Sahm; David T W Jones; David Capper; Andreas von Deimling
Journal:  Acta Neuropathol Commun       Date:  2019-10-28       Impact factor: 7.801

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.